Business Context and Reporting Period
Company: Arvinas, Inc. (ARVN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 31, 2025
Event: Announcement of detailed results from the Phase 3 VERITAC-2 clinical trial for vepdegestrant (ARV-471), an investigational PROTAC ER degrader for ER+/HER2- advanced or metastatic breast cancer. The data was presented at ASCO and published in the New England Journal of Medicine.
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on clinical trial results and regulatory strategy. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Results
The filing details significant clinical outcomes from the VERITAC-2 trial (624 patients, 26 countries) comparing vepdegestrant monotherapy to fulvestrant in patients who progressed on prior CDK4/6 inhibitors:
- ESR1 Mutation (ESR1m) Population: Vepdegestrant demonstrated a statistically significant improvement in Progression-Free Survival (PFS), reducing the risk of disease progression or death by 43% (HR=0.57; P<0.001). Median PFS was 5.0 months versus 2.1 months for fulvestrant.
- Intent-to-Treat (ITT) Population: The trial did not reach statistical significance for PFS improvement (HR=0.83; P=0.07). Median PFS was 3.7 months for vepdegestrant versus 3.6 months for fulvestrant.
- Response Rates (ESR1m): Clinical Benefit Rate (CBR) was 42.1% vs. 20.2%; Objective Response Rate (ORR) was 18.6% vs. 4.0%.
- Safety: Vepdegestrant was generally well tolerated. Most common TEAEs were fatigue (26.6%), increased ALT (14.4%), and increased AST (14.4%). Grade 4 TEAEs occurred in 1.6% of vepdegestrant patients vs. 2.9% for fulvestrant.
Guidance, Outlook, and Risks
Regulatory Outlook: Arvinas and Pfizer plan to engage with regulatory authorities and intend to submit a New Drug Application (NDA) to the FDA in the second half of 2025.
Management Commentary: The Company believes the data supports vepdegestrant as a potential best-in-class monotherapy for the second-line ESR1m setting.
Risks: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks discussed in quarterly and annual reports, including regulatory approval uncertainties and clinical development risks.
Investor Verification Checklist
- Verify the specific criteria for the ESR1m population versus the ITT population to understand the scope of the positive PFS results.
- Confirm the timeline for the planned NDA submission in H2 2025 and any potential regulatory feedback received.
- Review the full safety data in the press release (Exhibit 99.1) regarding treatment discontinuation rates (2.9% for vepdegestrant vs. 0.7% for fulvestrant).
- Monitor the upcoming conference call on June 2, 2025, for additional management commentary on commercialization strategy.
- Check subsequent filings for financial impact, as this 8-K does not disclose revenue or cash position.